IMPACT BIOMEDICAL INC (IBO) Fundamental Analysis & Valuation

NYSEARCA:IBO • US45259L2051

Current stock price

0.66 USD
+0.01 (+1.13%)
At close:
0.6599 USD
0 (-0.02%)
After Hours:

This IBO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. IBO Profitability Analysis

1.1 Basic Checks

  • In the past year IBO has reported negative net income.
  • In the past year IBO has reported a negative cash flow from operations.
  • IBO had negative earnings in each of the past 5 years.
  • In the past 5 years IBO always reported negative operating cash flow.
IBO Yearly Net Income VS EBIT VS OCF VS FCFIBO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 2025 -5M -10M -15M -20M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -68.01%, IBO is doing worse than 73.82% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -93.89%, IBO is doing worse than 65.44% of the companies in the same industry.
Industry RankSector Rank
ROA -68.01%
ROE -93.89%
ROIC N/A
ROA(3y)-66.5%
ROA(5y)-43.4%
ROE(3y)-230.4%
ROE(5y)-143.72%
ROIC(3y)N/A
ROIC(5y)N/A
IBO Yearly ROA, ROE, ROICIBO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 2025 -100 -200 -300 -400 -500

1.3 Margins

  • The Gross Margin of IBO (84.38%) is better than 87.43% of its industry peers.
  • The Profit Margin and Operating Margin are not available for IBO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.38%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IBO Yearly Profit, Operating, Gross MarginsIBO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 2025 0 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. IBO Health Analysis

2.1 Basic Checks

  • IBO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for IBO has been increased compared to 1 year ago.
  • The debt/assets ratio for IBO has been reduced compared to a year ago.
IBO Yearly Shares OutstandingIBO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
IBO Yearly Total Debt VS Total AssetsIBO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

2.2 Solvency

  • An Altman-Z score of 4.04 indicates that IBO is not in any danger for bankruptcy at the moment.
  • IBO's Altman-Z score of 4.04 is fine compared to the rest of the industry. IBO outperforms 69.63% of its industry peers.
  • IBO has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of IBO (0.05) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 4.04
ROIC/WACCN/A
WACC9.49%
IBO Yearly LT Debt VS Equity VS FCFIBO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 2025 0 10M 20M 30M

2.3 Liquidity

  • IBO has a Current Ratio of 0.35. This is a bad value and indicates that IBO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.35, IBO is doing worse than 94.24% of the companies in the same industry.
  • A Quick Ratio of 0.30 indicates that IBO may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.30, IBO is doing worse than 94.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.35
Quick Ratio 0.3
IBO Yearly Current Assets VS Current LiabilitesIBO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. IBO Growth Analysis

3.1 Past

  • IBO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.29%, which is quite impressive.
  • IBO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -13.82% yearly.
EPS 1Y (TTM)45.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%102.48%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-13.82%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IBO Yearly Revenue VS EstimatesIBO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2025 10K 20K 30K 40K

More info and screens

Find the best growth stocksShow best growing peers

0

4. IBO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IBO. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IBO Price Earnings VS Forward Price EarningsIBO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IBO Per share dataIBO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IBO Dividend Analysis

5.1 Amount

  • No dividends for IBO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IBO Fundamentals: All Metrics, Ratios and Statistics

IMPACT BIOMEDICAL INC

NYSEARCA:IBO (4/27/2026, 6:50:15 PM)

After market: 0.6599 0 (-0.02%)

0.66

+0.01 (+1.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners1.34%
Inst Owner Change0.13%
Ins Owners2.78%
Ins Owner Change-18.9%
Market Cap71.16M
Revenue(TTM)32.00K
Net Income(TTM)-11.84M
AnalystsN/A
Price TargetN/A
Short Float %16.17%
Short Ratio0.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2223.79
P/FCF N/A
P/OCF N/A
P/B 5.64
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.34
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS0.12
TBVpS-0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -68.01%
ROE -93.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.38%
FCFM N/A
ROA(3y)-66.5%
ROA(5y)-43.4%
ROE(3y)-230.4%
ROE(5y)-143.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.35
Quick Ratio 0.3
Altman-Z 4.04
F-Score6
WACC9.49%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%102.48%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-13.82%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-13.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y33.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.78%
OCF growth 3YN/A
OCF growth 5YN/A

IMPACT BIOMEDICAL INC / IBO Fundamental Analysis FAQ

What is the ChartMill fundamental rating of IMPACT BIOMEDICAL INC (IBO) stock?

ChartMill assigns a fundamental rating of 1 / 10 to IBO.


Can you provide the valuation status for IMPACT BIOMEDICAL INC?

ChartMill assigns a valuation rating of 0 / 10 to IMPACT BIOMEDICAL INC (IBO). This can be considered as Overvalued.


How profitable is IMPACT BIOMEDICAL INC (IBO) stock?

IMPACT BIOMEDICAL INC (IBO) has a profitability rating of 1 / 10.


How financially healthy is IMPACT BIOMEDICAL INC?

The financial health rating of IMPACT BIOMEDICAL INC (IBO) is 3 / 10.